Have a feature idea you'd love to see implemented?
Let us know!
REGN Regeneron Pharmaceuticals Inc
Price (delayed)
$691.57
Market cap
$76B
P/E Ratio
15.99
Dividend/share
N/A
EPS
$43.24
Enterprise value
$76.69B
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities , it
Highlights
REGN's price to earnings (P/E) is 37% lower than its last 4 quarters average of 25.2 and 9% lower than its 5-year quarterly average of 17.5
The equity has grown by 18% year-on-year and by 4% since the previous quarter
The quick ratio has contracted by 2% from the previous quarter
Key stats
What are the main financial stats of REGN
Market
Valuations
Earnings
Shares outstanding
109.89M
Market cap
$76B
Enterprise value
$76.69B
Price to earnings (P/E)
15.99
Price to book (P/B)
2.6
Price to sales (P/S)
5.4
EV/EBIT
15.24
EV/EBITDA
13.94
EV/Sales
5.54
Revenue
$13.85B
Gross profit
$11.93B
Net income
$4.65B
EBIT
$5.03B
EBITDA
$5.5B
Free cash flow
$3.46B
Per share
Balance sheet
Liquidity
EPS
$43.24
EPS diluted
$40.42
Free cash flow per share
$32.01
Book value per share
$266.03
Revenue per share
$128.1
TBVPS
$336
Total assets
$37.44B
Total liabilities
$8.12B
Debt
$2.7B
Equity
$29.33B
Working capital
$15.67B
Debt to equity
0.09
Current ratio
5.28
Quick ratio
4.34
Net debt/EBITDA
0.13
Margins
Efficiency
Dividend
EBITDA margin
39.7%
Gross margin
86.1%
Net margin
33.6%
Operating margin
28.7%
Return on assets
13.2%
Return on equity
16.8%
Return on invested capital
16.2%
Return on capital employed
14.9%
Return on sales
36.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
REGN stock price
How has the Regeneron Pharmaceuticals stock price performed over time
Intraday
0.55%
1 week
-1.69%
1 month
-1.46%
1 year
-26.65%
YTD
-2.91%
QTD
-2.91%
Financial performance
How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$13.85B
Gross profit
$11.93B
Operating income
$3.97B
Net income
$4.65B
Gross margin
86.1%
Net margin
33.6%
Regeneron Pharmaceuticals's net income has increased by 17% YoY and by 8% QoQ
Regeneron Pharmaceuticals's operating margin has decreased by 11% YoY
The net margin has increased by 10% YoY and by 5% from the previous quarter
Regeneron Pharmaceuticals's gross profit has increased by 6% YoY and by 2.6% from the previous quarter
Growth
What is Regeneron Pharmaceuticals's growth rate over time
Valuation
What is Regeneron Pharmaceuticals stock price valuation
P/E
15.99
P/B
2.6
P/S
5.4
EV/EBIT
15.24
EV/EBITDA
13.94
EV/Sales
5.54
REGN's price to earnings (P/E) is 37% lower than its last 4 quarters average of 25.2 and 9% lower than its 5-year quarterly average of 17.5
The company's EPS rose by 16% YoY and by 7% QoQ
REGN's price to book (P/B) is 37% less than its 5-year quarterly average of 4.1 and 34% less than its last 4 quarters average of 3.9
The equity has grown by 18% year-on-year and by 4% since the previous quarter
The P/S is 32% lower than the last 4 quarters average of 7.9 and 16% lower than the 5-year quarterly average of 6.4
The revenue has increased by 6% YoY and by 2.7% QoQ
Efficiency
How efficient is Regeneron Pharmaceuticals business performance
The company's return on sales rose by 7% YoY and by 5% QoQ
Regeneron Pharmaceuticals's return on invested capital has decreased by 4.1% YoY but it has increased by 3.2% QoQ
The return on assets has increased by 3.9% since the previous quarter
Regeneron Pharmaceuticals's return on equity has increased by 3.1% QoQ
Dividends
What is REGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for REGN.
Financial health
How did Regeneron Pharmaceuticals financials performed over time
REGN's total assets is up by 16% year-on-year and by 3.8% since the previous quarter
Regeneron Pharmaceuticals's total liabilities has increased by 12% YoY and by 3% QoQ
The debt is 91% less than the equity
The equity has grown by 18% year-on-year and by 4% since the previous quarter
REGN's debt to equity is down by 18% YoY and by 10% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.